NCT00439231View on ClinicalTrials.gov

Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

November 30, 2010

Conditions
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma
Interventions
DRUG

Lenalidomide

Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Georg Aue, M.D.

NIH

NCT00439231 - Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter